Edition:
United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

15.70USD
26 May 2017
Change (% chg)

$-0.14 (-0.88%)
Prev Close
$15.84
Open
$15.80
Day's High
$15.90
Day's Low
$15.40
Volume
61,598
Avg. Vol
128,682
52-wk High
$17.19
52-wk Low
$7.20

Latest Key Developments (Source: Significant Developments)

Omeros completes IGA nephropathy cohort in OMS721 phase 2 clinical trial
Wednesday, 17 May 2017 07:00am EDT 

May 17 (Reuters) - Omeros Corp :Omeros announces completion of IGA nephropathy cohort in OMS721 phase 2 clinical trial.Omeros Corp - additional positive results support rapid advancement to phase 3 trial.Omeros Corp - consistent with all other OMS721 clinical trials, no significant safety concerns have been observed.Omeros Corp - most commonly reported adverse events in trial are fatigue and anemia.  Full Article

Omeros reports Q1 revenue $12.3 million
Wednesday, 10 May 2017 04:02pm EDT 

May 10 (Reuters) - Omeros Corp :Omeros Corporation reports first quarter 2017 financial results.Q1 loss per share $0.34.Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Q1 revenue $12.3 million versus I/B/E/S view $13.3 million.  Full Article

Omeros reports more positive data in OMS721 phase 2 trial in renal diseases
Thursday, 30 Mar 2017 07:00am EDT 

Omeros Corp : Omeros reports more positive data in OMS721 phase 2 trial in renal diseases . Phase 3 program slated for this year . Consistent with all other OMS721 clinical trials, no significant safety concerns have been observed . Preparing breakthrough application and phase 3 protocol for discussion with FDA; phase 3 trial in IGAN expected to begin this year .New data corroborate and expand on trial results reported in Q4 of 2016.  Full Article

Omeros to present results from dose-ranging stage of OMS721 Clinical Trial
Monday, 27 Mar 2017 07:00am EDT 

Omeros Corp : Omeros to present results from dose-ranging stage of oms721 clinical trial in atypical hemolytic uremic syndrome at world congress of nephrology . Omeros to present results from dose-ranging stage of oms721 clinical trial in atypical hemolytic uremic syndrome at world congress of nephrology . Omeros corp - mean change from baseline in platelet count was statistically significant as measured by area under curve .Omeros- renal replacement therapy able to be discontinued in 1 patient during oms721 treatment, renal function remained stable following completion of treatment.  Full Article

Omeros reports additional positive results from OMS721 Phase 2 trial
Wednesday, 1 Mar 2017 07:00am EST 

Omeros Corp : Omeros reports additional positive results from OMS721 phase 2 trial in patients with stem cell transplant-associated thrombotic microangiopathy . Omeros Corp - total of ten serious adverse events have been reported, none considered related to OMS721 treatment . Omeros Corp - two patients died of progression of cancer after less than three weeks of OMS721 treatment . Omeros Corp - one patient died of graft failure after completing study and positively responding to oms721 .Omeros Corp - none of these deaths was considered by investigators to be related to OMS721 treatment..  Full Article

Omeros announces pricing of public offering of common stock
Thursday, 11 Aug 2016 10:49am EDT 

Omeros Corp : Omeros announces pricing of public offering of common stock .Pricing of a $40 million underwritten public offering of its common stock at a price to public of $11.50 per share.  Full Article

Omeros announces public offering of common stock
Wednesday, 10 Aug 2016 04:01pm EDT 

Omeros Corp : Omeros announces public offering of common stock . Intends to use net proceeds for funding research and development expenses for its clinical OMS721 program and clinical trials .Says announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald & Co..  Full Article

Omeros confirms late-stage development plan for OMS721 with EMA
Thursday, 28 Jul 2016 09:27am EDT 

Omeros Corp : Omeros corporation confirms oms721 phase 3 development plan with european medicines agency . Initiation of enrollment in ahus phase 3 clinical trial is planned for late this year . Omeros plans to commercialize oms721 initially for administration as a subcutaneous injection .One single-arm, open-label phase 3 pivotal trial planned to support approval in both europe and u.s..  Full Article

Omeros enters debt financing transaction for $20 mln in additional funds
Tuesday, 17 May 2016 07:00am EDT 

Omeros Corp : Entered into an amendment to its existing credit facility to provide company with an additional $20 million in unrestricted cash . Will issue warrants to lenders, exercisable for 7 years for up to 100,602 shares of common stock at an exercise price per share of $9.94 . Expects funding will occur on may 18, 2016. .Omeros announces debt financing transaction for $20 million in additional funds.  Full Article

Omeros Corporation reports Q1 loss per share $0.54
Tuesday, 10 May 2016 07:29am EDT 

Omeros Corp : Omeros corporation reports first quarter 2016 financial results . Q1 loss per share $0.54 . Q1 revenue $7.4 million versus I/B/E/S view $8.8 million . Q1 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S ."continue to expect that we will reach cash-flow positive status later this year, fully funding our pipeline".  Full Article

More From Around the Web

BRIEF-Omeros completes IGA nephropathy cohort in OMS721 phase 2 clinical trial

* Omeros announces completion of IGA nephropathy cohort in OMS721 phase 2 clinical trial